AstraZeneca plc vs Twist Bioscience Corp — how do they compare? AstraZeneca plc trades at $157.96 (market cap $248.14B), while Twist Bioscience Corp trades at $123 (market cap $7.72B). The key difference: AstraZeneca plc is far larger — about 32.1× Twist Bioscience Corp's market cap, and AstraZeneca plc pays a 2.01% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| AZN | TWST | |
|---|---|---|
Market Cap | $248.14B | $7.72B |
Sector | Health | Health |
52-Week High | $209.48 | $124.88 |
52-Week Low | $147.06 | $24.16 |
Enterprise Value | $275.41B | $7.65B |
Dividend Yield | 2.01% | — |
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →